Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the…

By S. Schnittger, C. Schoch, M. Dugas, W. Kern, P. Staib, Christian Wuchter, H. Löffler, C. Sauerland, Hubert Serve, T. Büchner and 2 more. Blood, 2002

1,024 citations recorded by the source corpus.

Subfields: Genetics, Hematology

View Paper: https://www.semanticscholar.org/paper/ea448516075363e78ed5b62bfc7164a5c1515cf5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Ching-Hon Pui
2. William E. Evans
3. D. Teachey
4. Marco A. Marra
5. S. Maude
6. S. Grupp

Citations in the corpus

• Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. (2005, neutral): “Median platelet count, 1000/ L (range) 30 (1-619)”
• Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia (2012, background): “FLT3 ITDs and increased expression of wild-type FLT3 are also present in high-risk acute myeloid and lymphoblastic leukemia (Schnittger et al., 2002; Armstrong et al., 2003; Paietta et al., 2004; Zhang et al., 2012).”
• Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). (2006, neutral): “Median platelet count, 109/L (range) 68 (7-302)* 56 (3-514) 47 (5-372) 46 (4-1430)”
• The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. (2008, neutral): “Secondary 116 94 (81) 13 (11) 8 (7) 1 (1) — 93 68 (73) 25 (27) —”